GSK, Vir seek FDA EUA for VIR-7831 for early treatment of Covid-19
VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal antibody intended for treating mild-to-moderate Covid-19
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 Mar 21
VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal antibody intended for treating mild-to-moderate Covid-19
26 Mar 21
Breyanzi is a chimeric antigen receptor (CAR) T cell therapy designed to target CD19, a biomarker for normal…
22 Mar 21
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that keeps lymphocytes out of the blood
19 Mar 21
MHRA concluded that there is no evidence that blood clots in veins are occurring more than expected in…
15 Mar 21
Earlier, the Republic of Ireland took a similar decision over reports of blood clotting in adults in Norway
12 Mar 21
EC authorised the vaccine to prevent the Covid-19 in people aged 18 years and older, in all 27…
08 Mar 21
The company claimed that its Yescarta is the first chimeric antigen receptor (CAR) T-cell therapy approved for patients…
04 Mar 21
The expanded approval is based on CROWN trial, which showed that treatment using Lorbrena reduced the risk of…
01 Mar 21
The Covid-19 vaccine has been granted emergency use authorisation after evaluation of safety, effectiveness and manufacturing quality by…
25 Feb 21
AbbVie claims that HUMIRA is the first and only subcutaneous biologic treatment for active ulcerative colitis in paediatric…